Special ReportNot FDA ApprovedTrending

Retatrutide: The Most Powerful Weight Loss Drug in Development, And Why You Should Wait

Clinical trial data show 28.7% average body weight loss, the highest ever recorded. But retatrutide is not FDA-approved, cannot be legally prescribed, and compounded versions are explicitly prohibited. Here is what the science shows and what the timeline realistically looks like.

Retatrutide is among the most frequently discussed topics in patient consultations this quarter. Interest has been driven by extensive health media coverage of Phase 3 clinical trial data showing weight loss at a magnitude not previously recorded in pharmacological research. The context worth establishing at the outset: retatrutide is an investigational compound. It is not FDA-approved, cannot be legally prescribed, and compounded versions are prohibited under federal law. The excitement is understandable; the appropriate response is patience.

Phase 3 TRIUMPH-4 data released in December 2025 showed an average body weight loss of 28.7% over 68 weeks, the highest ever recorded in an obesity drug trial. For comparison, semaglutide (Wegovy) produces approximately 15% weight loss and tirzepatide (Zepbound) approximately 22%. The mechanism behind this performance is retatrutide’s classification as a triple hormone receptor agonist: it simultaneously activates GLP-1 (satiety and blood sugar regulation), GIP (fat storage modulation), and glucagon (metabolic rate). The glucagon pathway is the distinguishing feature, the addition that likely accounts for the substantially greater weight loss compared to dual agonists, and that also introduces a more complex pharmacological profile requiring thorough evaluation before approval.

Several TRIUMPH trials are still reporting through 2026. Eli Lilly is expected to file a New Drug Application with the FDA in late 2026 or early 2027, though no official date has been confirmed. Standard FDA review takes 10–12 months. Based on these timelines, commercial availability before late 2027 is unlikely; early 2028 is the more realistic projection.

What Patients Are Hearing

Retatrutide has received extensive coverage in health and longevity media, with commentary that generally reflects genuine excitement about the trial data. The consistent message from clinically grounded voices in this space mirrors our own: the efficacy signals are remarkable, the safety profile requires fuller evaluation, and unregulated compounded products carry unacceptable risk. This is not a controversial clinical position.

Infectious DiseaseActive OutbreakCurrent

Cyclospora: A Major Foodborne Outbreak Is Spreading Across the United States

Nearly 7,000 cases of cyclosporiasis have been reported across 34 states since May 1, 2026, more than six times the case count at this time last year. The source has not yet been identified. Here is what the illness is, how to recognize it, and what to do.

As of July 13, 2026, the CDC has confirmed 1,645 laboratory-confirmed domestically acquired cases of cyclosporiasis reported across 34 states, while acknowledging that more than 5,100 additional cases require further analysis to confirm as domestically acquired. The national total of confirmed and probable cases has surpassed 6,700, compared to just 249 cases reported at this same point in 2025. This is an active, rapidly evolving outbreak.

The CDC has posted an investigation notice about a cluster of more than 400 cases in at least four states, Michigan, Ohio, West Virginia, and Kentucky, that appear epidemiologically linked, suggesting a common food source. Michigan health officials have identified lettuce or salad greens as a possible source in that state’s outbreak, though other foods have not been ruled out. No food supplier has been publicly identified as of this writing.

What Is Cyclospora Cayetanensis?

Cyclosporiasis is an intestinal infection caused by the microscopic parasite Cyclospora cayetanensis. People become infected by consuming water or raw food, most commonly raw produce, contaminated with the parasite. Food picks up Cyclospora most often through water supplies contaminated with human feces. The parasite is not transmitted from person to person. Previous outbreaks have been linked to bagged salads, leafy greens, fresh basil, fresh cilantro, raspberries, and green onions.

Symptoms. Diarrhea is the primary symptom, it can be acute or prolonged, lasting weeks or months if untreated. Symptoms typically begin within one week of ingesting the parasite. Other symptoms include loss of appetite, nausea, fatigue, bloating, and low-grade fever. A distinctive feature of cyclosporiasis is that the watery diarrhea may stop and restart unpredictably, which sometimes leads patients to assume they have recovered when the infection remains active. Among the confirmed 2026 cases, 141 patients, approximately 9%, have required hospitalization. No deaths have been reported.

Diagnosis and treatment. Cyclospora is not detected on standard stool ova-and-parasite tests. A specific request for Cyclospora testing must be made when ordering stool studies, as laboratory detection requires modified acid-fast staining or PCR. Cyclosporiasis is treatable with antibiotics, trimethoprim-sulfamethoxazole (TMP-SMX) is the standard treatment, and clinicians may also recommend anti-diarrheal medications. Treatment significantly shortens illness duration. Hydration is important throughout.

Practical food safety during this outbreak. Until a specific source is identified, the CDC recommends standard food safety precautions with fresh produce: wash all fruits and vegetables thoroughly under running water before eating, even if pre-washed or bagged. Cooking produce eliminates the risk entirely. Those with compromised immune systems, who are pregnant, elderly, or have chronic gastrointestinal conditions should be particularly attentive to symptoms following consumption of raw leafy greens and fresh herbs.

CardiologyJust Approved

Enlicitide: The First Oral PCSK9 Inhibitor, Now FDA-Approved

The FDA approved enlicitide (Merck’s MK-0616) on July 17, 2026, the first oral PCSK9 inhibitor ever approved. For patients who have not reached their LDL targets on statins alone, this represents a genuinely new option that does not require injections.

PCSK9 inhibitors are a class of drugs that dramatically lower LDL cholesterol by blocking a protein that degrades LDL receptors on the liver. When PCSK9 is inhibited, more LDL receptors remain active, clearing more LDL from the bloodstream. The two existing PCSK9 inhibitors, evolocumab (Repatha) and alirocumab (Praluent), are injections administered every two to four weeks, and they lower LDL cholesterol by 50–60%. They are effective and well-tolerated, but the injection requirement has limited adoption. Enlicitide changes that.

The oral route is the central practice-level change. Injectable PCSK9 inhibitors have long faced adherence and access friction tied to administration and specialty distribution, and a daily tablet shifts both substantially. Enlicitide is a once-daily oral macrocyclic peptide, taken as a tablet, with no fasting requirement.

What the Phase 3 Trials Showed

Enlicitide decanoate (formerly known as MK-0616) has been shown to significantly reduce LDL cholesterol levels by a maximum of 66% from baseline with a good safety and tolerability profile. In the CORALreef Lipids trial, enlicitide produced a 54% mean reduction in non-HDL cholesterol and a 50% reduction in apolipoprotein B from baseline at week 24. Results in the CORALreef HeFH trial, which enrolled patients with heterozygous familial hypercholesterolemia, a genetic condition that causes severely elevated LDL, were comparable. The safety profile was generally similar to placebo. The most common adverse reactions occurring more often than placebo were dizziness (9% vs 4%) and diarrhea (7% vs 2%).

Who is a candidate. Enlicitide is indicated for adults with primary hyperlipidemia, including those with heterozygous familial hypercholesterolemia, who require additional LDL lowering beyond what statins and ezetimibe provide. It is intended to be used alongside statin therapy in most patients, not as a replacement for it. A cardiovascular outcomes trial, CORALreef Outcomes, is ongoing and will determine whether the LDL reduction translates to reduction in heart attacks and strokes, as it has with the injectable PCSK9 inhibitors.

What is not yet known. The CORALreef Outcomes cardiovascular events trial is still enrolling and will not report for several years. The injectable PCSK9 inhibitors have robust outcomes data, FOURIER and ODYSSEY demonstrated significant reduction in major cardiovascular events. Enlicitide’s lipid-lowering magnitude is comparable, and by the well-established relationship between LDL reduction and cardiovascular risk, the outcomes benefit is expected, but not yet formally confirmed for this specific drug.

What Patients Are Hearing

This approval has received significant cardiology media attention because the adherence problem with injectable PCSK9 inhibitors has been real and well-documented. Real-world studies of evolocumab and alirocumab consistently show discontinuation rates far higher than in clinical trials, primarily attributed to injection burden and specialty pharmacy logistics. A daily pill addresses both. The efficacy data is strong and the safety profile is favorable. Cost and insurance coverage, historically a barrier for this drug class, remain to be determined.

Nutrition ScienceIn Your Feed

Ultra-Processed Foods and Your Brain: Research That’s Getting Harder to Ignore

2025 studies linked heavy ultra-processed food consumption to faster cognitive decline and higher mortality. What the evidence says, and simple, lasting steps that make a difference.

The term “ultra-processed” has been gaining traction for a few years, but the research backing it up has gotten harder to dismiss. Studies published in 2025 found heavy consumption associated with a 15% higher all-cause mortality risk and a 28% faster rate of cognitive decline. These are observational findings, they show association, not proven cause and effect, but the consistency across dozens of independent research groups, and the plausibility of the biological mechanisms involved, has moved this from fringe nutrition science to the 2026 Dietary Guidelines for Americans. That’s a meaningful shift.

The practical problem is that “ultra-processed” can feel abstract until you’re standing in a grocery aisle. A rough working definition: if the ingredient list has more than five items and most of them aren’t recognizable as food, you’re in the zone. Flavored yogurts, packaged deli meats, most breakfast cereals, instant noodles, chips, many protein bars. The good news is that small changes compound faster than people expect.

What Patients Are Hearing

Nutrition-focused health media has been circulating a useful heuristic: if your great-grandmother wouldn’t recognize it as food, reconsider. Blunt, but the published research broadly supports the spirit of it. The gut microbiome framing, that ultra-processed foods disrupt the microbial diversity associated with good metabolic and immune health, is also getting more airtime, and the evidence for that mechanism is increasingly solid.

1. Pick one swap, not ten. Replace the flavored yogurt with plain Greek and fruit, or swap afternoon chips for nuts. One consistent change beats a whole new diet that lasts a week.
2. Anchor meals to protein and vegetables. Grilled fish, chicken, or legumes over vegetables and whole grains. Simple combinations that naturally crowd out the processed defaults.
3. Look at ingredient lists, not just calories. Fewer ingredients, more recognizable ones. That’s a more useful signal than macros for this particular purpose.
4. Solve the convenience gap before it happens. Ultra-processed foods exist because they’re fast. Pre-cooked grains, boiled eggs, cut fruit, and a bag of nuts solve the same problem without the trade-offs.

Longevity & AgingHeadlines

Longevity Medicine: What’s Real, What’s Expensive, and What’s Both

Full-body MRIs, NAD+ supplements, biological age tests, VO2 max optimization, a practical guide to what the evidence actually supports.

Longevity medicine has gone mainstream. A wave of popular health podcasts has brought clinical concepts, VO2 max, Zone 2 training, ApoB testing, metabolic health panels, to a general audience, which is mostly a good thing. People are thinking more carefully about what they’re doing with their bodies in their 40s and 50s. That matters. Where it gets messier is when the marketing runs ahead of the science, which in this space it frequently does.

What Patients Are Hearing

The longevity framework getting the most traction focuses on four physical pillars: strength, stability, Zone 2 aerobic fitness, and VO2 max. The core claim, that VO2 max is one of the strongest predictors of all-cause mortality, and that what you do physically in your 40s and 50s largely determines how you function in your 70s, is well-supported in the literature. That’s not hype. Also getting attention: expanding standard lipid panels to include ApoB, fasting insulin, and inflammatory markers. Again, clinically reasonable for the right patients.

Also Worth Knowing

The behavioral side of longevity, consistent sleep, morning light exposure to anchor circadian rhythm, cold and heat exposure for cardiovascular adaptation, has been getting more nuanced treatment in health media, including an increasingly honest acknowledgment that most longevity supplements have far weaker evidence than the habits they’re supposed to replace. That’s a welcome development. The basics are still the basics.

TechnologyPatient Questions

Your Smartwatch Says You Have AFib. Now What?

Wearable devices are catching real conditions earlier, but they also generate false alarms. How to interpret what your device tells you, and when to call us.

Consumer wearable devices, Apple Watch, Garmin, Whoop, Oura Ring, now generate continuous data on heart rhythm, blood oxygen, sleep, and resting heart rate. A growing number of patients are presenting alerts or trend data from these devices for clinical interpretation, which raises an important and genuinely useful conversation about what these signals mean.

The underlying technology is clinically meaningful. Wearable ECG has been shown in prospective studies to detect atrial fibrillation in patients who were unaware of the diagnosis, and early AFib identification carries real stroke prevention value. The limitation is not the technology itself but the interpretation of individual readings without clinical context. A blood oxygen reading of 93% during vigorous outdoor activity differs substantially from the same reading at rest during sleep. A resting heart rate of 48 bpm is appropriate for a well-conditioned patient and potentially concerning in another. Context, including your history, medications, and baseline, is what distinguishes a meaningful signal from noise.

What Patients Are Hearing

Health media has moved toward framing wearable data as a longitudinal readiness signal, tracking sleep quality, heart rate variability trends, and resting heart rate over time, rather than as a diagnostic tool responding to individual readings. This framing is clinically appropriate. Personal baseline trends over days and weeks carry more interpretive weight than any isolated data point.

DermatologyJust ApprovedSeasonal

American Sunscreens Are Finally Getting Better, What You Need to Know

On June 9, 2026, the FDA approved bemotrizinol, the first new active sunscreen ingredient permitted in the United States in over 25 years. It has been used safely in European and Asian sunscreens since 1999. Here is what this means, what is still not approved, and what patients should do right now.

Patients who travel to Europe or who purchase imported Korean skincare products frequently ask why their sunscreens feel different, lighter, less white, more comfortable on skin, and why the SPF protection seems more comprehensive. The answer has been a regulatory gap that persisted for over two decades: the European Union regulates sunscreens as cosmetics, enabling rapid innovation and ingredient approval, while the FDA regulates them as over-the-counter drugs, requiring a more extensive safety review process. The result is that while Europe has approved 28 UV filter ingredients, the U.S. had only 16, and several of the most effective modern filters remained unavailable in American products.

In June 2026, the FDA added bemotrizinol to the list of permitted sunscreen ingredients, the first new UV filter allowed in American sunscreens in more than 25 years. Europe approved the same ingredient in 2000, and it has been a workhorse filter in Asian and European sunscreens ever since.

What Makes Bemotrizinol Different

Bemotrizinol, also known by the trade names Tinosorb S and Parsol Shield, is a broad-spectrum UV filter that covers both UVB and UVA wavelengths. It has been used safely in sunscreens across Europe and Asia since 1999 and has amassed a 27-year safety track record abroad. Crucially, it is highly photostable, it does not break down in sunlight the way avobenzone (the most common UVA filter in current U.S. sunscreens) does. Avobenzone degrades rapidly on skin and requires additional stabilizing ingredients to maintain effectiveness, which affects both performance and formulation feel. Bemotrizinol does not have this limitation, and it also helps stabilize other filters in the formula. The FDA has approved it at concentrations up to 6%.

What is still not approved in the U.S. The other modern filters that make Korean and European sunscreens superior, Uvinul A Plus, Tinosorb M (bisoctrizole), Mexoryl 400, and others, are still not on the U.S. approved list. Dermatologists hope to see Mexoryl SX (ecamsule) and Mexoryl XL (drometrizole trisiloxane) approved next. The bemotrizinol approval is accurately described as the beginning of a catch-up process, not a comprehensive update. The American Academy of Dermatology called it “an important public health step” that will help “save the lives of Americans from skin cancer, one of the most preventable cancers.”

What about European or Asian sunscreens purchased online? Under the Federal Food, Drug, and Cosmetic Act, it is technically illegal to sell sunscreens in the U.S. that are not FDA-approved, including products with ingredients such as Tinosorb M or Mexoryl SX. The FDA does permit personal importation of OTC products for individual use on a case-by-case basis, but products purchased through third-party online sellers may not be the authentic formulations they claim to be. This is a matter of individual decision-making that patients should be informed about rather than one we can recommend categorically.

Questions From Our Patients

Ask Your GMP Doctor

Four More Things Worth Knowing

Your Quarterly Wellness Calendar

One clinical focus per month, specific, evidence-based, and actionable.